GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » 12-1 Month Momentum %

MAIA Biotechnology (MAIA Biotechnology) 12-1 Month Momentum % : 16.96% (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-05-25), MAIA Biotechnology's 12-1 Month Momentum % is 16.96%.

The industry rank for MAIA Biotechnology's 12-1 Month Momentum % or its related term are showing as below:

MAIA's 12-1 Month Momentum % is ranked better than
77.86% of 1477 companies
in the Biotechnology industry
Industry Median: -25.71 vs MAIA: 16.96

Competitive Comparison of MAIA Biotechnology's 12-1 Month Momentum %

For the Biotechnology subindustry, MAIA Biotechnology's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MAIA Biotechnology's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's 12-1 Month Momentum % falls into.



MAIA Biotechnology  (AMEX:MAIA) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MAIA Biotechnology  (AMEX:MAIA) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


MAIA Biotechnology 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


MAIA Biotechnology (MAIA Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
MAIA Biotechnology Inc is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606